BRD-810

DB23607ExperimentalSmall molecule

BRD-810 is an experimental small molecule inhibitor of MCL-1 for the treatment of cancer. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1).

Mechanism: Pharmacologically active on Induced myeloid leukemia cell differentiation protein Mcl-1
Curator reviewed
Formula / weight: C₃₉H₄₄ClFN₄O₅ · 703.25 g/mol (avg)
Code names: BRD-810

Resolves to

Compound

CAS2329719-65-3ChEMBLCHEMBL5889903

Structure

InChIKeyRQXSLNDYCDRXAC-MGBGTMOVSA-NSMILESCCC1=C2C(=NN1C)[C@@H](CCN1CCOCC1)OCCCCN1C(C(O)=O)=C(CCCOC3=C4C=CC(F)=CC4=CC=C3)C3=C1C2=C(Cl)C=C3

Targets

Q07820MCL1

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with BRD-810, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account